MediWound Reports Third Quarter 2026 Financial Results

MediWound reported revenue of $8.1 million for the first nine months of 2026, compared to $15.1 million in the same period of 2025, primarily due to lower development services revenue related to the U.S. government. The company recorded a net loss of $16.3 million, or $1.27 per share, for the period. As of September 30, 2026, the company held $28.4 million in cash and cash equivalents. In November 2026, MediWound strengthened its balance sheet by closing an underwritten public offering that generated $17.25 million in gross proceeds. Additionally, the company noted that NexoBrid procurement under its partner Vericel's contract with BARDA began in the third quarter, and it received $3.3 million in non-dilutive funding from the U.S. Department of War to develop a room-temperature-stable NexoBrid formulation.